BORA PHARMACEUTICALS LTD - Asset Resilience Ratio
BORA PHARMACEUTICALS LTD (6472) has an Asset Resilience Ratio of 0.14% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read BORA PHARMACEUTICALS LTD (6472) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2024)
This chart shows how BORA PHARMACEUTICALS LTD's Asset Resilience Ratio has changed over time. See BORA PHARMACEUTICALS LTD shareholders equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down BORA PHARMACEUTICALS LTD's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see BORA PHARMACEUTICALS LTD (6472) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$63.40 Million | 0.14% |
| Total Liquid Assets | NT$63.40 Million | 0.14% |
Asset Resilience Insights
- Limited Liquidity: BORA PHARMACEUTICALS LTD maintains only 0.14% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
BORA PHARMACEUTICALS LTD Industry Peers by Asset Resilience Ratio
Compare BORA PHARMACEUTICALS LTD's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Daihan Pharmaceutical Co.Ltd
KQ:023910 |
Drug Manufacturers - Specialty & Generic | 11.95% |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA |
Drug Manufacturers - Specialty & Generic | 16.92% |
|
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SHE:000999 |
Drug Manufacturers - Specialty & Generic | 5.22% |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538 |
Drug Manufacturers - Specialty & Generic | 2.69% |
|
Zhejiang Xianju Pharmaceutical Co Ltd
SHE:002332 |
Drug Manufacturers - Specialty & Generic | 6.02% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Hainan Honz Pharmaceutical Co
SHE:300086 |
Drug Manufacturers - Specialty & Generic | 0.27% |
|
Guangdong Lifestrong Pharmacy Co. Ltd.
SHE:301111 |
Drug Manufacturers - Specialty & Generic | 7.85% |
Annual Asset Resilience Ratio for BORA PHARMACEUTICALS LTD (2019–2024)
The table below shows the annual Asset Resilience Ratio data for BORA PHARMACEUTICALS LTD.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-09-30 | 0.20% | NT$92.34 Million ≈ $2.91 Million |
NT$45.60 Billion ≈ $1.44 Billion |
-1.17pp |
| 2023-09-30 | 1.37% | NT$342.63 Million ≈ $10.79 Million |
NT$25.05 Billion ≈ $789.28 Million |
+0.28pp |
| 2022-09-30 | 1.09% | NT$247.63 Million ≈ $7.80 Million |
NT$22.76 Billion ≈ $717.10 Million |
+1.09pp |
| 2021-09-30 | 0.00% | NT$78.00K ≈ $2.46K |
NT$7.37 Billion ≈ $232.27 Million |
+0.00pp |
| 2020-09-30 | 0.00% | NT$64.00K ≈ $2.02K |
NT$7.00 Billion ≈ $220.67 Million |
-0.89pp |
| 2019-09-30 | 0.89% | NT$30.00 Million ≈ $945.16K |
NT$3.38 Billion ≈ $106.57 Million |
-- |
About BORA PHARMACEUTICALS LTD
Bora Pharmaceuticals Co., LTD. engages in contract development, manufacture, and sale of pharmaceuticals in Europe, the United States, Taiwan, and internationally. The company operates through Sales, CDMO, and Other segments. It manufactures and sells generic, brand, and over the counter (OTC) drugs. The company also offers contract development and manufacturing services and technical services fo… Read more